Histamine dihydrochloride is under clinical development by AgoneX Biopharmaceuticals and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Histamine dihydrochloride’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Histamine dihydrochloride overview

Histamine dihydrochloride is under development of the treatment of migraine prophylaxis, treatment of Parkinson's disease, amyotrophic lateral sclerosis (ALS), multiple sclerosis, attention deficit hyperactivity disorder (ADHD), chronic traumatic encephalopathy, schizophrenia, epilepsy, Alzheimer's disease and autism. The drug candidate is administered subcutaneously. The drug candidate is a salt of histamine. It acts by targeting histamine receptor.

It was also under development for the treatment addiction.

AgoneX Biopharmaceuticals overview

AgoneX Biopharmaceuticals is a clinical stage biotechnology and healthcare company that develops and commercializes pharmaceutical products. The company develops drugs for the treatment and prevention of migraine headaches, Parkinson’s disease, Alzheimer’s disease, autism and other indications. It provides pipeline portfolio such as products for various indications such as epilepsy, schizophrenia, multiple sclerosis and amyotrophic lateral sclerosis, among others. The company also develops histamine dihydrochloride a product which helps to treat various indications. AgoneX Biopharmaceuticals is headquartered in Santa Monica, California, the US.

For a complete picture of Histamine dihydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.